Evidence map›Paper›PMID 40417719›Full record

ArticleVascular investigation and therapy

Recent Innovations and Advances in Arteriovenous Fistula Creation: A Narrative Review.

Cayetana Lazcano-Etchebarne, Edouard Aboian, David Strosberg, Nirvana Sadaghianloo, Andrew W Schwartz, Bryan Ho, Yuichi Ohashi, Masaki Kano, Luis Gonzalez, Hualong Bai and 1 more

Abstract read
In one paragraph

Article in Vascular investigation and therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Cayetana Lazcano-EtchebarneVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Edouard AboianDepartment of Surgery, Yale School of Medicine, New Haven, Connecticut, United States.
David StrosbergDepartment of Surgery, Yale School of Medicine, New Haven, Connecticut, United States.
Nirvana SadaghianlooVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Andrew W SchwartzVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Bryan HoVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Yuichi OhashiVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Masaki KanoVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Luis GonzalezVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Hualong BaiVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.
Alan DardikVascular Biology and Therapeutics Program, Yale School of Medicine, New Haven, Connecticut, United States.

Funding

Manipulating the matrix to improve arteriovenous fistula patencyR01HL144476 · NHLBI · YALE UNIVERSITY · PI Alan Dardik · 2019 to 2026
$5.6M
Research Training in AnesthesiaT32GM086287 · NIGMS · YALE UNIVERSITY · PI ROBERT SCHONBERGER · 2009 to 2026
$3.7M
Adaptive immunity regulates arteriovenous fistula remodelingR01HL162580 · NHLBI · YALE UNIVERSITY · PI Alan Dardik · 2023 to 2026
$3.0M
Short Term Research Training: Students in Health Professional SchoolsT35DK104689 · NIDDK · YALE UNIVERSITY · PI LLOYD G CANTLEY, Sarwat I Chaudhry · 2015 to 2026
$2.6M
Enhancing venous adaptation to the arterial environmentR01HL128406 · NHLBI · YALE UNIVERSITY · PI DARDIK, ALAN · 2016 to 2019
$1.9M
NHLBI NIH HHS R01 HL128406NHLBI NIH HHS R01 HL144476NHLBI NIH HHS R01 HL162580NIDDK NIH HHS T35 DK104689NIGMS NIH HHS T32 GM086287
6 · The paper itself

Abstract

Arteriovenous fistulae (AVF) are the gold standard for vascular access among patients requiring hemodialysis; however, AVF have high primary failure rates. Novel approaches and technologies to improve AVF patency include modifications to open approaches, such as the radial artery deviation and reimplantation fistula, and percutaneous approaches, such as the endovascular AVF. Despite these advances, these modifications are limited in reducing neointimal hyperplasia, stenosis, or thrombosis, and thus have limited capacity to improve AVF maturation and utilization; as such, vascular access requires continued innovation. Emerging strategies to prevent neointimal hyperplasia include drug-embedded and bioresorbable perivascular wraps. Increased rates of AVF failure among women highlight sex differences in the biology of AVF maturation and suggest additional targets to improve outcomes. Other advances in understanding the biology of AVF maturation suggest potentialized approaches for patients, including immune system modulation and stem cell therapies. Although these emerging technologies may improve AVF maturation and utilization, longer-term patency and freedom from complications such as central vein stenosis and dialysis access associated distal ischemia emphasize the critical need for continued scientific inquiry and technological development to optimize vascular access.

Indexed as

arteriovenous fistulaendovascularfistula maturationsex differencessurgical innovationsvascular access

Identifiers

PMID40417719
PMCPMC12103191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.